The IPO Buzz: Jyong Biotech (MENS) Prices IPO at $7.50 – Low End – & Soars on NASDAQ
Jyong Biotech Ltd. (MENS), a Taiwan-based biotech developing drugs to treat benign prostate hyperplasia and to prevent prostate cancer, priced its IPO at $7.50 – the low end of its range – and sold 2.7 million shares – the number of shares in the prospectus – to raise $20.0 million on Monday night, June 16, […]
June 17, 2025 Read More